Aspirin headache revived: Study finds CVD preventive effect

But findings are less applicable as patients age, says Australian expert

Aspirin for primary prevention of cardiovascular disease could be beneficial in a small group of patients provided they have a higher baseline risk of CV events, an NZ study suggests.


The findings, which run ­counter to Australian guidelines advising against aspirin for primary prevention, highlight the importance of individualised benefit-harm analyses in high-risk patients, the University of Auckland researchers say.

They analysed data from 245,000 primary care patients aged between 30 and 79 who had their five-year CVD risk assessed using the